Contemporary strategies in the diagnosis and management of heart failure

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Heart failure (HF) is an important public health problem, and strategies are needed to improve outcomes and decrease health care resource utilization and costs. Its prevalence has increased as the population ages, and HF continues to be associated with a high mortality rate and frequent need for hospitalization. The total cost of care for patients with HF was 30.7 billion in 2012, and it is estimated to more than double to 69.8 billion by 2030. Given this reality, there has been recent investigation into ways of identifying and preventing HF in patients at risk (stage A HF) and those with cardiac structural and functional abnormalities but no clinical HF symptoms (stage B). For patients who have symptoms of HF (stage C), there has been important research into the most effective ways to decongest patients hospitalized with acute decompensated HF and prevent future hospital readmissions. Successful strategies to treat patients with HF and preserved ejection fraction, which has increased in prevalence, continue to be sought. We are in the midst of a rapid evolution in our ability to care for patients with end-stage HF (stage D) because of the introduction of and improvements in mechanical circulatory support. Left ventricular assist devices used as destination therapy offer an important therapeutic option to patients who do not qualify for heart transplant because of advanced age or excessive comorbidity. This review provides a thorough update on contemporary strategies in the diagnosis and management of HF by stage (A to D) that have emerged during the past several years.

Original languageEnglish (US)
Pages (from-to)662-676
Number of pages15
JournalMayo Clinic Proceedings
Volume89
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Heart Failure
Patient Care
Patient Acceptance of Health Care
Patient Readmission
Heart-Assist Devices
Health Resources
Health Care Costs
Comorbidity
Hospitalization
Public Health
Transplants
Costs and Cost Analysis
Mortality
Therapeutics
Research
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Contemporary strategies in the diagnosis and management of heart failure. / Dunlay, Shannon M; Pereira, Naveen Luke; Kushwaha, Sudhir S.

In: Mayo Clinic Proceedings, Vol. 89, No. 5, 2014, p. 662-676.

Research output: Contribution to journalArticle

@article{5978b356e79a4e17ac55823aa39c1498,
title = "Contemporary strategies in the diagnosis and management of heart failure",
abstract = "Heart failure (HF) is an important public health problem, and strategies are needed to improve outcomes and decrease health care resource utilization and costs. Its prevalence has increased as the population ages, and HF continues to be associated with a high mortality rate and frequent need for hospitalization. The total cost of care for patients with HF was 30.7 billion in 2012, and it is estimated to more than double to 69.8 billion by 2030. Given this reality, there has been recent investigation into ways of identifying and preventing HF in patients at risk (stage A HF) and those with cardiac structural and functional abnormalities but no clinical HF symptoms (stage B). For patients who have symptoms of HF (stage C), there has been important research into the most effective ways to decongest patients hospitalized with acute decompensated HF and prevent future hospital readmissions. Successful strategies to treat patients with HF and preserved ejection fraction, which has increased in prevalence, continue to be sought. We are in the midst of a rapid evolution in our ability to care for patients with end-stage HF (stage D) because of the introduction of and improvements in mechanical circulatory support. Left ventricular assist devices used as destination therapy offer an important therapeutic option to patients who do not qualify for heart transplant because of advanced age or excessive comorbidity. This review provides a thorough update on contemporary strategies in the diagnosis and management of HF by stage (A to D) that have emerged during the past several years.",
author = "Dunlay, {Shannon M} and Pereira, {Naveen Luke} and Kushwaha, {Sudhir S.}",
year = "2014",
doi = "10.1016/j.mayocp.2014.01.004",
language = "English (US)",
volume = "89",
pages = "662--676",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - Contemporary strategies in the diagnosis and management of heart failure

AU - Dunlay, Shannon M

AU - Pereira, Naveen Luke

AU - Kushwaha, Sudhir S.

PY - 2014

Y1 - 2014

N2 - Heart failure (HF) is an important public health problem, and strategies are needed to improve outcomes and decrease health care resource utilization and costs. Its prevalence has increased as the population ages, and HF continues to be associated with a high mortality rate and frequent need for hospitalization. The total cost of care for patients with HF was 30.7 billion in 2012, and it is estimated to more than double to 69.8 billion by 2030. Given this reality, there has been recent investigation into ways of identifying and preventing HF in patients at risk (stage A HF) and those with cardiac structural and functional abnormalities but no clinical HF symptoms (stage B). For patients who have symptoms of HF (stage C), there has been important research into the most effective ways to decongest patients hospitalized with acute decompensated HF and prevent future hospital readmissions. Successful strategies to treat patients with HF and preserved ejection fraction, which has increased in prevalence, continue to be sought. We are in the midst of a rapid evolution in our ability to care for patients with end-stage HF (stage D) because of the introduction of and improvements in mechanical circulatory support. Left ventricular assist devices used as destination therapy offer an important therapeutic option to patients who do not qualify for heart transplant because of advanced age or excessive comorbidity. This review provides a thorough update on contemporary strategies in the diagnosis and management of HF by stage (A to D) that have emerged during the past several years.

AB - Heart failure (HF) is an important public health problem, and strategies are needed to improve outcomes and decrease health care resource utilization and costs. Its prevalence has increased as the population ages, and HF continues to be associated with a high mortality rate and frequent need for hospitalization. The total cost of care for patients with HF was 30.7 billion in 2012, and it is estimated to more than double to 69.8 billion by 2030. Given this reality, there has been recent investigation into ways of identifying and preventing HF in patients at risk (stage A HF) and those with cardiac structural and functional abnormalities but no clinical HF symptoms (stage B). For patients who have symptoms of HF (stage C), there has been important research into the most effective ways to decongest patients hospitalized with acute decompensated HF and prevent future hospital readmissions. Successful strategies to treat patients with HF and preserved ejection fraction, which has increased in prevalence, continue to be sought. We are in the midst of a rapid evolution in our ability to care for patients with end-stage HF (stage D) because of the introduction of and improvements in mechanical circulatory support. Left ventricular assist devices used as destination therapy offer an important therapeutic option to patients who do not qualify for heart transplant because of advanced age or excessive comorbidity. This review provides a thorough update on contemporary strategies in the diagnosis and management of HF by stage (A to D) that have emerged during the past several years.

UR - http://www.scopus.com/inward/record.url?scp=84901611885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901611885&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2014.01.004

DO - 10.1016/j.mayocp.2014.01.004

M3 - Article

C2 - 24684781

AN - SCOPUS:84901611885

VL - 89

SP - 662

EP - 676

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -